Spine Surgery and Related Research
Online ISSN : 2432-261X
ISSN-L : 2432-261X
TECHNICAL NOTE
Posterior Spinal Correction and Fusion Surgery in Patients with Spinal Muscular Atrophy-Associated Scoliosis for Whom Treatment with Nusinersen Was Planned
Shuhei MachidaMasayuki MiyagiWataru SaitoAyano MatsuiTakayuki ImuraGen InoueToshiyuki NakazawaEiki ShirasawaShinsuke IkedaAyumu KawakuboAkiyoshi KurodaYuji YokozekiYusuke MimuraKentaro UchidaTsutomu AkazawaMasashi Takaso
著者情報
ジャーナル オープンアクセス

2021 年 5 巻 2 号 p. 109-113

詳細
抄録

Introduction: Spinal muscular atrophy (SMA) is defined as a neuromuscular disorder induced by progressive weakness of the skeletal muscle and is usually accompanied by progressive spinal deformity including scoliosis. The newly developed Nusinersen, which is the first approved drug worldwide for SMA, requires accurate intrathecal injection, which is sometimes difficult in patients with severe spinal deformity.

Technical Note: For an accurate intrathecal approach in patients who have spinal fusion surgery to treat neuromuscular scoliosis, we have combined an L3 laminectomy with spinal correction and fusion surgery. Here, we review four cases of SMA in patients who underwent the additional L3 laminectomy during surgery to treat spinal scoliosis. A successful intrathecal approach was made using fluoroscopic guidance in all four patients, who were then administered with Nusinersen.

Conclusions: Our findings show that additional lumbar laminectomy during surgery for spinal scoliosis has effectively allowed for intrathecal injection of Nusinersen.

Fullsize Image
著者関連情報
© 2021 The Japanese Society for Spine Surgery and Related Research.

SSRR is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. Anyone may download, reuse, copy, reprint, or distribute articles published in the journal for not-for-profit purposes if they cite the original authors and source properly. If you remix, transform, or build upon the material, you may not distribute the modified material.
https://creativecommons.org/licenses/by-nc-nd/4.0/
前の記事 次の記事
feedback
Top